The lead investigator of the STS/ACC TVT Registry study presented at ACC.17 explains why its findings suggest valve-in-valve TAVR might be the treatment of choice for inoperable and even high-risk patients.
The transcatheter approach to aortic valve replacement in intermediate-risk patients appears to curb the risk of these potentially deadly effects, new subanalyses presented at ACC.17 show.
Make room in your schedule at the American College of Cardiology meeting for key presentations ranging from the SPIRE 1 and 2 trials to ABSORB III two-year results and more.
This free Thursday dinner symposium at ACC.17 can help attendees make the most of the many advancements discussed at the larger meeting. The course directors explain why you shouldn’t miss it.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
From heart benefits of diabetes drugs to leadless pacing to expanding populations for TAVR, 2016 was a dynamic year in cardiovascular care. Cleveland Clinic experts reflect on a dozen key developments.
A global registry study has found high rates of mortality from infective endocarditis following TAVR. A study co-author and an ID specialist discuss the study’s surprises and how to curb post-TAVR infection risk.
Our series of infographics profiling the nation’s No. 1 heart program turns to cardiovascular medicine. Here’s the lowdown on some key recent outcomes and volumes.
PARTNER 2A and SAPIEN 3 findings have filled the headlines following ACC.16. Two investigators in the studies — Drs. Lars Svensson and Samir Kapadia — join a Cleveland Clinic panel to put them in context for clinicians.
Launching a TAVR program is complex. Here’s how a team of Cleveland Clinic expert advisors helped a tertiary care medical center in Missouri navigate the process and achieve strong early TAVR outcomes.
The cardiac surgeon who led this multicenter, 11,600-patient analysis says it pinpoints an “opportunity to do better” for the large subgroup of TAVR patients with chronic lung disease.